Showing results (151-160 of 169) with videos related to
Sort By:
Pageof 17
AIDS (London, England)|October 7, 2025
Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized studyDebbie Hagins, Mezgebe Berhe, Gordon E Crofoot, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 20, 2014
Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of AmericaGregory M Lucas, Michael J Ross, Peter G Stock, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 16, 2019
Insomnia as an Independent Predictor of Incident Cardiovascular Disease in HIV: Data From the Veterans Aging Cohort StudyBrittanny M Polanka, Suman Kundu, Kaku A So-Armah, et al.Plos One|February 10, 2023
Non-alcoholic fatty liver disease is not associated with impairment in health-related quality of life in virally suppressed persons with human immune deficiency virusSamer Gawrieh, Kathleen E Corey, Jordan E Lake, et al.Brain, Behavior, and Immunity|May 20, 2023
Effect of modernized collaborative care for depression on depressive symptoms and cardiovascular disease risk biomarkers: eIMPACT randomized controlled trialJesse C Stewart, Jay S Patel, Brittanny M Polanka, et al.JAMA Cardiology|August 25, 2016
Association Between Depressive Disorders and Incident Acute Myocardial Infarction in Human Immunodeficiency Virus-Infected Adults: Veterans Aging Cohort StudyTasneem Khambaty, Jesse C Stewart, Samir K Gupta, et al.Psychological Medicine|September 10, 2024
Effect of depression treatment on health behaviors and cardiovascular risk factors in primary care patients with depression and elevated cardiovascular risk: data from the eIMPACT trialMatthew D Schuiling, Aubrey L Shell, Christopher M Callahan, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyAnton Pozniak, Jose R Arribas, Joseph Gathe, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 26, 2024
Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label StudiesDahlene Fusco, Ivana Malenica, Huldrych F Günthard, et al.The Journal of Infectious Diseases|May 30, 2026
Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons with HIV Starting Antiretroviral Therapy in the United States and CanadaKassem Bourgi, Aihua Bian, Lakeisha Boyd, et al.Pageof 17